Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alumis Inc (ALMS)

Alumis Inc (ALMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 818,441
  • Shares Outstanding, K 104,393
  • Annual Sales, $ 0 K
  • Annual Income, $ -294,230 K
  • EBIT $ -456 M
  • EBITDA $ -453 M
  • 60-Month Beta -1.87
  • Price/Sales 25.68
  • Price/Cash Flow N/A
  • Price/Book 2.01

Options Overview Details

View History
  • Implied Volatility 156.45% (+61.01%)
  • Historical Volatility 58.24%
  • IV Percentile 44%
  • IV Rank 8.52%
  • IV High 1,143.00% on 11/12/25
  • IV Low 64.56% on 08/27/25
  • Expected Move (DTE 14) 0.47 (5.63%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 510
  • Volume Avg (30-Day) 265
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 6,601
  • Open Int (30-Day) 6,486
  • Expected Range 7.83 to 8.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.90
  • Number of Estimates 4
  • High Estimate -0.79
  • Low Estimate -1.04
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.40 +88.64%
on 11/07/25
8.40 -1.25%
on 12/04/25
+3.75 (+82.42%)
since 11/04/25
3-Month
3.76 +120.74%
on 09/30/25
8.40 -1.25%
on 12/04/25
+3.70 (+80.43%)
since 09/04/25
52-Week
2.76 +200.71%
on 06/24/25
10.49 -20.88%
on 04/04/25
+0.31 (+3.88%)
since 12/04/24

Most Recent Stories

More News
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 8.30 (+5.87%)
Alumis to Participate in Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 8.30 (+5.87%)
Alumis to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 8.30 (+5.87%)
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b...

ALMS : 8.30 (+5.87%)
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted...

ALMS : 8.30 (+5.87%)
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc.

ALMS : 8.30 (+5.87%)
Alumis to Present at the Jefferies Global Healthcare Investor Conference

ALMS : 8.30 (+5.87%)
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

ALMS : 8.30 (+5.87%)
Alumis Completes Merger with ACELYRIN

ALMS : 8.30 (+5.87%)
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

ALMS : 8.30 (+5.87%)

Business Summary

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN...

See More

Key Turning Points

3rd Resistance Point 9.37
2nd Resistance Point 8.89
1st Resistance Point 8.59
Last Price 8.30
1st Support Level 7.82
2nd Support Level 7.34
3rd Support Level 7.04

See More

52-Week High 10.49
Last Price 8.30
Fibonacci 61.8% 7.54
Fibonacci 50% 6.63
Fibonacci 38.2% 5.71
52-Week Low 2.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar